Skip to content

Congenital Uterine Anomalies & Pregnancy in Polycystic Ovarian Syndrome

Investigation of the Effect of Serum Androgen and Anti-Mullerian Hormone Levels on the Frequency of Müllerian Anomalies and Pregnancy Outcomes in Patients With Polycystic Ovarian Syndrome Undergoing Invitro Fertilization

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04776915
Acronym
CONUTA&PPCOS
Enrollment
100
Registered
2021-03-02
Start date
2020-10-14
Completion date
2022-02-01
Last updated
2021-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mullerian Anomaly of Uterus, Nec

Keywords

mullerian anomaly, PCOS, antimullerian hormone

Brief summary

Prospective research in which patients who applied to UUTF Gynecology and Obstetrics ART center for the treatment of infertility (inability to conceive despite one year of unprotected sexual intercourse), who will undergo IVF due to PCOS and unexplained infertility

Detailed description

As of 01/10/2020, IVF cycles of patients with PCOS (n = 105) and unexplained infertility (n = 105) who have applied to Bursa Uludag University Gynecology and Obstetrics Department, Reproductive Treatments Center, will be included in the study. Demographic data of all patients (age, BMI, smoking), presence of hyperandrogenism findings such as systemic diseases, hirsutism, alopecia, FSH, LH, LH/FSH ratio, estradiol levels, pregestational serum AMH levels, uterine anomalies detected by transvaginal USG or hysterosalpingography, controlled ovarian hyperstimulation protocols and doses; Besides, DHEA-S, Free Testosterone, 17-OH Progesterone levels will be recorded in patients diagnosed with PCOS. All these data are routine laboratory and imaging parameters of patients who underwent in vitro fertilization in our UYTE center. Pregnancy results of the patients (biochemical pregnancy, anembryonic pregnancy, abortion, clinical pregnancy, live birth), perinatal results and complications during clinical pregnancy, delivery ways, and newborn APGAR scores will be recorded. Results will be compared with patients in the control group diagnosed with unexplained infertility.

Interventions

DIAGNOSTIC_TESTUltrasound and Hysterosalpingography

Ultrasound and Hysterosalpingography

Sponsors

Uludag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Being in the age range of 20-40 * Need for an assisted reproductive method due to PCOS or unexplained infertility

Exclusion criteria

* \<20 years or \>40 years * Detecting a cause for infertility other than PCOS

Design outcomes

Primary

MeasureTime frameDescription
The rate of Mullerian AbnormalityOne yearESHRE&ESGE uterine abnormality classification

Countries

Turkey (Türkiye)

Contacts

Primary ContactGürkan Uncu, Prof.
guncu@gurkanuncu.org+902242952541
Backup ContactKiper Aslan, M.D.
kiperaslan@yahoo.com.tr+902242952541

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026